2.56
-0.0098(-0.38%)
Currency In USD
| Previous Close | 2.57 |
| Open | 2.49 |
| Day High | 2.68 |
| Day Low | 2.48 |
| 52-Week High | 4.2 |
| 52-Week Low | 1.87 |
| Volume | 16,402 |
| Average Volume | 28,280 |
| Market Cap | 22.01M |
| PE | -1.11 |
| EPS | -2.3 |
| Moving Average 50 Days | 2.62 |
| Moving Average 200 Days | 2.65 |
| Change | -0.01 |
If you invested $1000 in Lisata Therapeutics, Inc. (LSTA) 10 years ago, it would be worth $9.87 as of July 30, 2025 at a share price of $2.56. Whereas If you bought $1000 worth of Lisata Therapeutics, Inc. (LSTA) shares 5 years ago, it would be worth $72.02 as of July 30, 2025 at a share price of $2.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
GlobeNewswire Inc.
Jul 17, 2025 12:00 PM GMT
Compelling new preliminary data consistent with previously reported preclinical findings demonstrating certepetide’s potential ability to enhance the effectiveness of immunotherapyBASKING RIDGE, N.J. and SUBIACO, Australia, July 17, 2025 (GLOBE NEW
Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide
GlobeNewswire Inc.
Jul 15, 2025 12:00 PM GMT
Newly issued U.S. patent extends certepetide IP protection to 2040, with subsequent opportunity for patent term extension This patent covers novel cyclic peptides and their use in treating solid tumors BASKING RIDGE, N.J, July 15, 2025 (GLOBE NEWSW
Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer
GlobeNewswire Inc.
Jun 26, 2025 12:00 PM GMT
ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated